argenx SE (EBR:ARGX)
524.20
+0.80 (0.15%)
Apr 17, 2025, 5:35 PM CET
argenx SE Revenue
In the year 2024, argenx SE had annual revenue of $2.25B USD with 77.22% growth. argenx SE had revenue of $757.39M in the quarter ending December 31, 2024, with 81.26% growth.
Revenue
$2.25B
Revenue Growth
+77.22%
P/S Ratio
14.74
Revenue / Employee
$1.41M
Employees
1,599
Market Cap
32.01B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UCB SA | 6.15B |
Financière de Tubize | 13.26K |
Fagron NV | 871.96M |
Ion Beam Applications | 465.75M |
Nyxoah | 4.52M |
Hyloris Pharmaceuticals | 10.04M |
Onward Medical | 1.70M |
Sequana Medical NV | 433.50K |
argenx SE News
- 7 days ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 7 days ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 7 days ago - argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - GlobeNewsWire
- 8 days ago - Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug - Investor's Business Daily
- 8 days ago - Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe - Seeking Alpha
- 8 days ago - Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - Benzinga
- 8 days ago - US FDA approves syringe version of Argenx's immune disorder drug - Reuters
- 8 days ago - argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire